Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Neurosteroids such as dehydroepiandrosterone (DHEA) and allopregnanolone, which modulate neurotransmitter receptors in the brain. Bile acids such as taurocholic acid, which aid in lipid digestion and absorption in the intestine. Aminosteroid neuromuscular blocking agents (synthetic), such as pancuronium bromide, used in anesthesia to induce muscle relaxation. Steroidal antiandrogens (synthetic), such as cyproterone acetate, which block androgen receptors in hormone therapy. Steroidogenesis inhibitors (exogenous), such as alfatradiol, which suppress steroid synthesis for therapeutic purposes. Membrane sterols such as cholesterol (essential for cell membrane fluidity), ergosterol (a fungal membrane component), and various phytosterols (plant-derived sterols with cholesterol-lowering effects). Toxins such as steroidal saponins (plant defense compounds) and cardenolides/cardiac glycosides (which affect heart function). Steroids with an open-ring structure, known as secosteroids, include:
=== Foreign policy === Moore supports Israel's right to defend itself and a two-state solution to the Israeli–Palestinian conflict. In December 2022, he attended the Jewish Community Relations Council of Greater Washington's legislative breakfast, where he said he would be "very aggressive" in promoting trade between Maryland and Israel and promised that one of his first overseas visits would be to Israel. He expressed solidarity with Israel amid the October 7 attacks, and later supported an immediate ceasefire in the Gaza war. In October 2024, Moore criticized a Students for Justice in Palestine event at the University of Maryland, College Park held on the one-year anniversary of the October 7 attack to honor Palestinian civilians killed in the Gaza war, saying that he felt that it was an "inappropriate date for such an event". In May 2026, Moore told Politico that he believed Israeli Prime Minister Benjamin Netanyahu had committed war crimes in the Gaza war, citing his use of food as a negotiating tool. In April 2026, Moore criticized U.S. involvement in the 2026 Iran war, likening it to the war in Afghanistan and fearing it would evolve into "another forever war". He also criticized President Donald Trump for not clearly addressing the American people on what the U.S. is doing in Iran or what success looks like.
Partial smooth muscle differentiation of a fibroblastic cell Activation of a stellate cell (e.g. hepatic Ito cells or pancreatic stellate cells). Loss of contractile phenotype (or acquisition of "synthetic phenotype") of a smooth muscle cell. Direct myofibroblastic differentiation of a progenitor cell resident in a stromal tissue. Homing and recruitment of a circulating mesenchymal precursor which can directly differentiate as above or indirectly differentiate through the other cell types as intermediates. Epithelial to mesenchymal transdifferentiation (EMT) of an epithelial cell. Perhaps the most studied pathway of myofibroblast formation is TGF-beta1 dependent differentiation from fibroblast cells. Activation of the TGF-beta receptor 1 and TGF-beta receptor 2 leads to induction of the canonical SMAD2/SMAD3 pathway. Together with the co-activation of the non-canonical EGFR pathway, these events lead to upregulation of the ACTA2 gene and subsequent alpha smooth muscle actin protein production. Several regulators of the myofibroblast differentiation pathway have been described, including hyaluronan and CD44 co-receptor activation of EGFR.
== Further reading == Booth, Martin (2004). Cannabis: A History. Picador. ISBN 978-0-312-42494-7. Drake, Bill (2002). The Marijuana Food Handbook: A Guide for the Sensuous Connoisseur. Ronin Publishing. ISBN 978-0-914171-99-7. Grinspoon, Lester (1994). Marihuana Reconsidered. Quick American Archives. ISBN 978-0-932551-13-9.
Sources: en.wikipedia.org
John Lilley states, "...neutron-induced fission generates extra neutrons which can induce further fissions in the next generation and so on in a chain reaction. The chain reaction is characterized by the neutron multiplication factor k, which is defined as the ratio of the number of neutrons in one generation to the number in the preceding generation. If, in a reactor, k is less than unity, the reactor is subcritical, the number of neutrons decreases and the chain reaction dies out. If k > 1, the reactor is supercritical and the chain reaction diverges. This is the situation in a fission bomb where growth is at an explosive rate. If k is exactly unity, the reactions proceed at a steady rate and the reactor is said to be critical. It is possible to achieve criticality in a reactor using natural uranium as fuel, provided that the neutrons have been efficiently moderated to thermal energies." Moderators include light water, heavy water, and graphite. According to John C. Lee, "For all nuclear reactors in operation and those under development, the nuclear fuel cycle is based on one of three fissile materials, 235U, 233U, and 239Pu, and the associated isotopic chains. For the current generation of LWRs, the enriched U contains 2.5~4.5 wt% of 235U, which is fabricated into UO2 fuel rods and loaded into fuel assemblies." Lee states, "One important comparison for the three major fissile nuclides, 235U, 233U, and 239Pu, is their breeding potential.
=== Preclinical === AB-300 (AB300) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist AB-5006 (AX-5006) – Escherichia coli csgA protein aggregation inhibitor and gastrointestinal microbiome modulator [96] AEX-23 – orexin OX1 receptor agonist and α-synuclein aggregate/modulator [97] Afamelanotide ([Nle4,DPhe7]-α-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan; MT-I; Prenumbra; Scenesse) – melanocortin receptor agonist [98] Alpha-synuclein aggregation inhibitor (ACI-5755; morphomer α-synuclein) – α-synuclein inhibitor [99] BEBT-758 – RNA interference and α-synuclein expression inhibitor [100] Bevemipretide (SBT-272) – cardiolipin ligand and stabilizer [101] BSC-3301 – receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [102] BXQ-350 (SapC; SapC-DOPS; sphingolipid activator protein C) – sphingomyelin phosphodiesterase stimulant and sphingosine 1-phosphate stimulant [103] Cannabidiol (CBD) – cannabinoid receptor modulator and other actions [104] Carbon monoxide (CO; HBI-002) – heme oxygenase 1 modulator [105] CB-401 – amyloid β-protein modulator [106] CBT-102 – undefined mechanism of action [107] CJRB-301 (MRx-0005) – bacteria replacement and microbiome modulator [108] CJRB-302 (MRx-0029) – bacteria replacement and microbiome modulator [109] CK-0803 – regulatory T-lymphocyte replacement [110] CU-13001 – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [111] EHP-102 (VCE-003.2) – cannabinoid CB2 receptor agonist and peroxisome proliferator-activated receptor alpha (PPARα) modulator (cannabigerol (CBG) derivative) [112] Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist [113] FHL-401 – toll-like receptor 2 antagonist [114] FHL-701 – interleukin-12 (IL-12) subunit p40 inhibitor [115] FKK-01PD (FKK-01PD; TGHW-01AP; apomorphine prodrug) – non-selective dopamine receptor agonist and other actions [116] HT-4403 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [117] IC-100 (ICCN-100) – various actions [118] KFRX-05 (BK-40195) – leucine-rich repeat kinase 2 (LRRK2) inhibitor and protein tyrosine kinase inhibitor [119] KP-405 – undefined mechanism of action [120] LB-P4 – bacteria replacement and microbiome modulator [121] Mbiotix – bacteria replacement and microbiome modulator [122] ML-021 – muscarinic acetylcholine M4 receptor antagonist [123] MP-201 – 2,4-dinitrophenol (DNP) prodrug and various actions [124] NB-003 – gene transference and parkin protein replacement [125] NB-129 – undefined mechanism of action [126] NLY-02 – glial cell inhibitor [127] NLY-03 – undefined mechanism of action [128] NNI-362 – 70 kDa ribosomal protein S6 kinase modulator [129] NRG-5051 – mitochondrial permeability transition pore inhibitor [130] PMN-442 – monoclonal antibody against α-synuclein [131] PP-003 – α-synuclein degrader [132] Research programme: 3100 programme - DigmBio/Daegu Catholic University – G protein-coupled receptor (GPCR) modulators [133] Research programme: enzyme targeted therapeutics - Nitrase Therapeutics – enzyme modulators and α-synuclein inhibitors [134] Research programme: neurodegenerative disease therapeutics - Caraway Therapeutics – autophagy stimulants and MCOLN1 stimulants [135] RGL-193 – undefined mechanism of action [136] ST-502 – gene therapy and α-synuclein genetic transcription inhibitor [137] Tomaralimab (NM-101; NM-102; NM-103; OPN-305) – monoclonal antibody against toll-like receptor 2 [138] Zervimesine (CT-1812; Elayta) – sigma σ2 receptor antagonist [139]
This time, the internet amplified the proposition and spawned a hundred frauds and scams. However, their adoption of the "HGH" term has provided an easy way to distinguish the hype from the evidence. In 2003, growth hormone hit the news again, when the US FDA granted Eli Lilly approval to market Humatrope for the treatment of idiopathic short stature. The indication was controversial for several reasons, the primary one being the difficulty in defining extreme shortness with normal test results as a disease rather than the extreme end of the normal height range Recombinant growth hormone available in the U.S. (and their manufacturers) include Nutropin (Genentech), Humatrope (Eli Lilly and Company), Genotropin (Pfizer), Norditropin (Novo Nordisk), Tev-Tropin (Teva) and Saizen (Merck Serono). The products are nearly identical in composition, efficacy, and cost, varying primarily in the formulations and delivery devices. Somapacitan-beco (Sogroya) is the first once-per week subcutaneous human growth hormone (hGH) therapy that was approved in the United States. It was approved for medical use in the United States in August 2020.
== Further reading == Biochemistry textbook reference, from the NCBI bookshelf – Jeremy M. Berg; John L. Tymoczko; Lubert Stryer (eds.). "18.4. A Proton Gradient Powers the Synthesis of ATP". Biochemistry (5th ed.). W. H. Freeman. Archived from the original on August 3, 2007. A set of experiments aiming to test some tenets of the chemiosmotic theory – Ogawa S, Lee TM (August 1984). "The relation between the internal phosphorylation potential and the proton motive force in mitochondria during ATP synthesis and hydrolysis". The Journal of Biological Chemistry. 259 (16): 10004–10011. doi:10.1016/S0021-9258(18)90918-X. PMID 6469951.
=== Mark Conner-Healy === Mark Conner-Healy is played by Ames McNamara. The younger of Darlene's two children, Mark is a 10-year-old boy with a strong interest in fashion. His interest in things traditionally feminine, such as wearing makeup and skirts, is somewhat worrisome to his grandparents, with Roseanne worried that Mark will be bullied by his narrow-minded peers and Dan feeling that he needs to persuade the youngster to take on more masculine traits. Noticing a classmate make a snide comment to Mark on his first day at school in Lanford, Roseanne threatens his classmates by telling them she is a witch, while Dan gives Mark a pocket knife, which ultimately results in him being called to the principal's office and sent home from school for the day, much to Darlene's chagrin. Despite Roseanne and Dan's concerns, they express support and love for him. Mark is named after his deceased uncle, Mark Healy.
Sources: en.wikipedia.org
== History == There were two clinical trials that evaluated the benefits and side effects of bempedoic acid. The trial designs were similar. All enrolled subjects were on a lipid-lowering diet and taking the highest dose of a statin (drug commonly used to lower cholesterol) for high cholesterol. In both trials, subjects were randomly assigned to receive bempedoic acid or placebo tablets every day for 52-weeks. Neither the subjects nor the health care providers knew which treatment was being given. The trials measured percent change in LDL cholesterol (LDL-C) blood levels from baseline to week twelve and compared bempedoic acid to placebo. In one clinical trial, bempedoic acid reduced LDL-C by about 20 mg/dl compared to placebo and had a similar frequency of side effects to placebo, although a higher percentage of drug-receiving subjects dropped out of the study because of side effects (11% vs. 7% under placebo). In one randomized controlled trial, patients who could not tolerate therapy with statins had a reduced risk of major adverse cardiovascular events after being treated with bempedoic acid. In January 2020, the Committee for Medicinal Products for Human Use in the European Union recommended granting of a marketing authorization for bempedoic acid as both a standalone drug (brand name Nilemdo) and as a fixed-dose combination medication with ezetimibe (brand name Nustendi). Bempedoic acid was approved for use in the European Union in April 2020, and the combination bempedoic acid/ezetimibe was approved in March 2020.
== Plot == Timofey Berezin (Paddy Considine) works at a former top-secret, badly run and aged nuclear reprocessing facility plant in Skotoprigonyevsk-16, a former closed city and a naukograd. At the film's outset, he is exposed to radioactive contamination while selflessly trying to prevent a critical malfunction. The facility's managers tell him that his exposure was a survivable 100 rems, while accusing him of sabotage and suspending him without pay. Loyal coworkers, however, help Timofey discover the truth that he was exposed to 1,000 rems of radiation. Suffering from acute radiation poisoning, he has only days to live. Before Timofey's adoring wife, Marina (Radha Mitchell), is fully aware of his fate, he leaves for Moscow, on a mission to secure a better future for her and their young son. He hooks up with a small-time gangster, Shiv (Oscar Isaac), in hopes of finding a buyer for a selfmade canister of a little over 100 grams of weapons-grade plutonium salt he has stolen. It is 1995, only a few years after the dissolution of the Soviet Union, and they spend their time frequenting the hotels, nightclubs and private palaces of the new Moscow underworld, ricocheting between two rival crime lords (Nikolaj Lie Kaas and Steven Berkoff). However, what Timofey and Shiv never realize is that they are both caught in the same dilemma: trying to find a way free of a certain fate; hoping to do right by their loved ones before it is too late.
=== EU ban === The EU banned estradiol, progesterone, testosterone, zeranol, melengestrol acetate and trenbolone acetate. The first three are synthetic versions of endogenous hormones that are naturally produced in humans and animals, and in a wide range of foods, whereas the last two are synthetic, designed to mimic the behaviour of endogenous hormones. Zeranol (alpha-zearalanol) is produced semi-synthetically, but occurs naturally in some foods. It is one of several derivatives of zearalenone produced by certain Fusarium. Although its occurrence in animal products can be partly due to ingestion of such feeds, alpha-zearalanol can be produced endogenously in ruminants that have ingested zearalenone and some zearalenone derivatives. The EU did not impose an absolute ban. Under veterinary supervision, cattle farmers were permitted to administer the synthetic versions of natural hormones for cost-reduction and possibly therapeutic purposes, such as synchronising oestrus cycles. All six hormones were licensed for use in the US and in Canada. Under the Agreement on the Application of Sanitary and Phytosanitary Measures, signatories have the right to impose restrictions on health and safety grounds subject to scientific analysis. The heart of the dispute was the fact that risk analysis is statistical, and thus unable to determine with absolute certainty the absence of health risks. While US and Canada beef producers claimed that beef produced with the use of hormones was safe, the EU asserted that it was not safe.
In 1995, another Media Act was enacted, which saw the NOS's broadcasting duties greatly reduced, with the creation of the Nederlandse Programma Stichting (Netherlands Programming Service; NPS). The NPS took on the NOS's programming tasks concerning culture, art, children, education, and ethnic minorities, while the NOS concentrated on news, sports, and live events. A new Supervisory Board replaced the Board of Directors in 1998. The previous management was replaced with a three-man board, now charged with developing strategies and responsibility for all public output. Programming co-ordinators were appointed for each television and radio network and channel identities were created, largely replacing the varying on-air presentation of the pillar broadcasters. The broadcasting associations also have a degree of input through the Supervisory Board. In 2002, the coordination element of the public broadcast system, administered by the NOS was now made clearer with the creation of an umbrella organisation, Publieke Omroep (Public Broadcasting), while programme makers operated under the name "RTV NOS". The reorganisation loosened NOS from the public broadcasting system and reconstituted it as a neutral member of the NPO.
=== Agonists === Non-selective Galanin Galanin 1-15 fragment Galanin-like peptide - agonist at GAL1 and GAL2 but not GAL3 Galmic Galnon NAX 5055 D-Gal(7-Ahp)-B2 GAL1 selective M617 GAL1/2 selective M1154 - has no GalR3 interaction GAL2 selective Galanin 2-11 amide - also called AR-M 1896, anticonvulsant in mice, CAS# 367518–31–8 M1145 - selective compared to both GalR1 and GalR3 M1153 - selective compared to both GalR1 and GalR3 CYM 2503 (positive allosteric modulator)
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.